Latest Rosuvastatin Stories
Study highlights: -- People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels. -- Data indicates that people with only a 5 percent to 20 percent risk of having heart disease in the next ten years, but who have high levels of hsCRP could reduce the risk of heart attack and stroke by more than...
FLORHAM PARK, N.J., July 29 /PRNewswire/ -- Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S.
The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol.
WILMINGTON, Del., June 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 - the '314 patent) is valid and enforceable.
On Monday, researchers said they did not find evidence that cholesterol-reducing drugs can help extend the life of patients at risk of heart disease.
Analyzes the Effectiveness and Safety of Statin Use for Those Who Need It Recommendations for Choosing a 'Best Buy' Statin and Strategies for Money-Saving YONKERS, N.Y., June 29 /PRNewswire-USNewswire/ -- A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks.
MONTGOMERY, Ala. and INDIANAPOLIS, June 21 /PRNewswire-FirstCall/ -- Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that LIVALOÂ® (pitavastatin) tablets is now available in retail pharmacies throughout the United States.
ATLANTA, May 26 /PRNewswire/ -- Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced today that the investigational new drug PSD502, a topical metered dose spray which is being developed for the treatment of primary premature ejaculation (PE), will be the subject of five clinical presentations early next month.
NEW YORK, May 5 /PRNewswire-FirstCall/ -- Pfizer's Viagra and AstraZeneca's Nexium took the top-two slots on the new L2 Digital IQ Index for pharmaceutical brands, a first-of-its kind measurement of the digital competence of 51 pharma brands across eight therapeutic categories, designed to provide an actionable metric to optimize pharmaceutical digital ROI. The ranking, created by think tank L2 in partnership with leading media agency PHD Network, evaluated pharmaceutical brands' digital...
LONDON, April 27 /PRNewswire/ -- CRESTOR(TM) (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk* of having a first cardiovascular event.
- A volcanic mudflow.